A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
10/2001
10/18/2001	WO2001076638A2 Compositions for drug delivery
10/18/2001	WO2001076637A2 Peptide conjugates for drug delivery
10/18/2001	WO2001076564A1 Microprojectile delivery system and particulate product
10/18/2001	WO2001076451A2 Diagnosis of diseases associated with metabolism
10/18/2001	WO2001076361A1 Animal and cell models for type ii diabetes and their use
10/18/2001	WO2001040313A3 Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
10/18/2001	WO2001038548A3 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
10/18/2001	WO2001036626A3 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds
10/18/2001	WO2001036455A3 Chlamydia antigens and corresponding dna fragments and uses thereof
10/18/2001	WO2001031015A3 36p6d5: secreted tumor antigen
10/18/2001	WO2001025435A3 In vivo treatment of joint disease using interleukin-1 receptor antagonists
10/18/2001	WO2001023540A3 P-glycoproteins and uses thereof
10/18/2001	WO2001022090A9 Method for identifying compounds useful in the therapy of bone disorders
10/18/2001	WO2001021201A3 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
10/18/2001	WO2001012803A3 Methods and compositions for restoring antibiotic susceptibility in glycopeptide-resistant enterococcus
10/18/2001	WO2001004145A3 Glutx polypeptide family and nucleic acids encoding same
10/18/2001	WO2000069898A8 Molecular interactions in allergy cells
10/18/2001	WO2000057837A9 Compositions and methods for effecting the levels of cholesterol
10/18/2001	WO2000044782A9 Ewing's tumour antigen, nucleic acid and antibodies
10/18/2001	WO2000043498A9 Human liver progenitors
10/18/2001	WO2000037635A3 Genetic suppressor elements against human immunodeficiency virus
10/18/2001	WO2000032233A3 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
10/18/2001	WO2000020041A9 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent
10/18/2001	US20010032339 Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
10/18/2001	US20010032338 Screening method for PPAR-gamma ligands
10/18/2001	US20010032337 Introduction of exogenous nucleotide sequences into a genome by microinjection of infectious retrovirus into the perivitelline space of the egg; making a bovine embryo; use to confer disease resistance, for example
10/18/2001	US20010031741 Methods for treatment of lysosomal storage diseases
10/18/2001	US20010031740 Mixture containing organic halide
10/18/2001	US20010031261 Use of genetically engineered antibodies to treat multiple myeloma
10/18/2001	US20010031039 Electromagnetic object detector provided with an additional electrode and intended for a medical radiation apparatus
10/18/2001	DE10016083A1 Nicht-menschliches Tiermodell für Wachstumsdefizienz und Defekte der Informationsverarbeitung oder der kognitiven Funktion und seine Verwendung A non-human animal model for Wachstumsdefizienz and defects of the information processing or the cognitive function and its use
10/18/2001	DE10015906A1 Directed gene transfer to eukaryotic cells, useful for antisense inhibition of specific genes, comprises using a complex of polyethyleneimine, nucleic acid and monoclonal antibodies
10/18/2001	DE10007234A1 Peptid und dafür kodierende Nukleinsäure zur Bestimmung, Diagnostik und Therapie von Erkrankungen des Nervensystems Peptide and nucleic acid coding for determining diagnosis and treatment of diseases of the nervous system
10/18/2001	CA2414652A1 Animal and cell models for type ii diabetes and their use
10/18/2001	CA2406485A1 Hpv-specific short-mers
10/18/2001	CA2406352A1 Peptide conjugates for drug delivery
10/18/2001	CA2406233A1 Compositions for drug delivery
10/18/2001	CA2406058A1 Tm4sf receptor polynucleotides, polypeptides, and antibodies
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405870A1 Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
10/18/2001	CA2405800A1 Novel secreted protein
10/18/2001	CA2405181A1 Human pyruvate dehydrogenese phosphatase
10/18/2001	CA2405124A1 Gene coding for erbin, and diagnostic and therapeutic uses thereof
10/18/2001	CA2405104A1 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
10/18/2001	CA2404988A1 Listeria monocytogenes genome, polypeptides and uses
10/18/2001	CA2403946A1 Genes expressed in foam cell differentiation
10/18/2001	CA2403317A1 Mutant bank
10/18/2001	CA2403140A1 Novel chromosomal vectors and uses thereof
10/18/2001	CA2402410A1 The high bone mass gene of 11q13.3
10/17/2001	EP1146125A1 Poxvirus with targeted infection specificity
10/17/2001	EP1146122A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
10/17/2001	EP1146055A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
10/17/2001	EP1145721A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
10/17/2001	EP1144998A2 Neisseria genomic sequences and methods of their use
10/17/2001	EP1144690A1 Antisense modulation of cellular inhibitor of apoptosis-2 expression
10/17/2001	EP1144682A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
10/17/2001	EP1144678A2 Susceptibility to psoriasis
10/17/2001	EP1144654A2 Serine protease
10/17/2001	EP1144645A1 Neisseria meningitidis polypeptide basb052
10/17/2001	EP1144642A2 Compounds and methods for treatment and diagnosis of chlamydial infection
10/17/2001	EP1144638A2 Chlamydia antigens and corresponding dna fragments and uses thereof
10/17/2001	EP1144634A2 Novel complex-forming proteins
10/17/2001	EP1144633A1 Polypeptide
10/17/2001	EP1144632A2 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
10/17/2001	EP1144631A2 Insulin-synthesis genes
10/17/2001	EP1144628A2 Human vanilloid receptor gene
10/17/2001	EP1144626A2 Methods of monitoring hiv drug resistance
10/17/2001	EP1144623A1 Method and medicament for inhibiting the expression of a defined gene
10/17/2001	EP1144621A2 Genetic suppressor elements against human immunodeficiency virus
10/17/2001	EP1144618A1 Method for isolating apoptosis-inducing dna sequences and detection system
10/17/2001	EP1144614A2 33 human secreted proteins
10/17/2001	EP1144609A2 Chimeric antisense oligonucleotides and cell transfecting formulations thereof
10/17/2001	EP1144603A2 Protease
10/17/2001	EP1144600A2 Akt-3 nucleic acids, polypeptides, and uses thereof
10/17/2001	EP1144594A1 Transgenic circulating endothelial cells
10/17/2001	EP1144591A2 Low oxygen culturing of cells
10/17/2001	EP1144447A2 Tuberculosis diagnostic test
10/17/2001	EP1144441A2 Disintegrin homologs
10/17/2001	EP1144414A2 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids
10/17/2001	EP1144014A2 Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors
10/17/2001	EP1144012A1 Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery
10/17/2001	EP1144009A2 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
10/17/2001	EP1143994A2 Use of apoptosis inducing agents in the treatment of (auto)immune diseases
10/17/2001	EP1143797A1 Methods for reducing adverse side effects associated with cellular transplantation
10/17/2001	EP1007097B1 Formulation of stabilised cationic transfection agent(s)/nucleic acid particles
10/17/2001	CN1318105A Methods for down-regulating osteoprotegerin ligand activity
10/17/2001	CN1318099A LY6H gene
10/17/2001	CN1317976A Multicomponent vaccines
10/17/2001	CN1073154C Superoxide dismutase-4
10/16/2001	US6303582 Compositions and methods for nucleic acid delivery to the lung
10/16/2001	US6303571 To screen for antibacterial compounds; genetic immunization; therapy and prophylaxis
10/16/2001	US6303379 Transfected cells for use in treatment of genetic disorder
10/16/2001	US6303376 Stimulation using cellular dna synthesis or repair mechanisms
10/16/2001	US6303374 By hybridization with nucleic acid; controlling apoptosis and programmed cell death; alzheimers, parkinsons, autoimmune, and viral diseases; cancer; amyotrophic lateral sclerosis
10/16/2001	US6303371 Method of purified rAAV vector production in non-human cell line transfected with cocksackie and adenovirus receptor
10/16/2001	US6303362 Generating genetically engineered viral genome; provide plasmids, incubate plasmids with restriction enzyme, mix products and ligate, screen libraries
10/16/2001	US6303344 Methods and compositions for polypeptide engineering
10/16/2001	US6303338 Nucleotide sequences coding polypeptide for use in diagnosis and treatment of mammary gland cancer, and pathologic defects
10/16/2001	US6303334 Nucleotide sequences coding polypeptides for use in as a viricide and in gene therapy
10/16/2001	US6303333 Expression vector which codes polypeptides for the diagnosis and treatment of cancer, dietetics, inflammation, cardiovascular disorders, crohn's diseases, neuropathies and immune defects

1 ... 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 ... 870